FDA Approves ResolutionMD for Diagnosis on Mobile Devices
Calgary Scientific’s ResolutionMD received FDA clearance for diagnosis on mobile devices for most imaging modalities.
ResolutionMD, an enterprise image-viewing solution, has been approved by the U.S. Food and Drug Administration (FDA) for diagnosis on mobile devices for most imaging modalities.
Calgary Scientific, Inc., the company behind ResolutionMD, worked with multiple radiologists worldwide to clinically validate the solution before submitting it to the FDA. ResolutionMD allows doctors to securely view patient images and reports from a variety of computers and mobile devices. It also offers the ability to collaborate with other practitioners and diagnose from any location.
The mobile medical diagnosis software of ResolutionMD can be integrated into any EMR and plugged into existing distributed storage systems. The FDA’s safety and effectiveness review found ResolutionMD to be substantially equivalent to PACS or dedicated diagnostic workstations.
ResolutionMD has been cleared to diagnose modalities such as CR, DR, radio-fluoroscopy, angiography, ultrasound, nuclear medicine, endoscopy and ophthalmology.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Ultrasound-Guided Thermal Ablation Shows Low Recurrence of Thyroid Carcinoma at Five Years
June 16th 2025In a meta-analysis involving over 2,200 patients with T1NoMo papillary thyroid carcinoma, researchers noted 2 percent recurrence and no cases of lymph node metastasis five years after ultrasound-guided thermal ablation.
